Table of Contents
This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the industry have been highlighted. This analysis provides a quantitative market basis for biotechnology, pharmaceutical, adjuvant and gene delivery companies to make strategic choices about DNA vaccine technologies and markets. Rapid technological and structural changes occurring in the vaccine industry are strong driving forces for revitalizing this particular market and providing new growth opportunities.
Use this report to:
- Gain detailed information about the role of DNA vaccines within the overall vaccine industry.
- Analyze the importance of biotechnology and pharmaceutical firms.
- Understand the technology and market dynamics within this industry to develop the informed strategic plans and actions.
- Learn about the DNA vaccine products that are commercial or likely to be commercialized within the next five years.
- The global market for DNA vaccines was valued at $243.7 million in 2013 and is expected to increase to $305.3 million in 2014, and further to $2.7 billion by 2019, a compound annual growth rate (CAGR) of 54.8% over the five-year period from 2014 through 2019.
- Research tools as a segment of the market is expected to grow at a five-year CAGR of 11.1% from 2014 to 2019 and is expected to reach $182.3 million by 2014 and nearly $308 million by 2019.
- The clinical vaccines segment of the market is expected to be $123.0 million in 2014. With a CAGR of 81.2%, BCC Research expects this market will reach nearly $2.4 billion by 2019.
STUDY GOALS AND OBJECTIVES
BCC Research’s goal for this study is to determine the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. Our particular interest is to analyze and quantify the DNA vaccines market potential by disease type, end-use market and technology. We also identify emerging growth opportunities in DNA vaccine delivery technologies, adjuvants and synthetic genes. Our key objective is to present a comprehensive analysis of the emerging DNA vaccine
industry, with an emphasis on products and technologies that are commercially important in the 2014 to 2019 time period. The role of DNA vaccines within the overall vaccine industry is examined. We highlight high growth and market potential segments of the industry. This analysis provides a quantitative market basis for biotechnology,
pharmaceutical, adjuvant and gene delivery companies to make strategic choices about DNA vaccine technologies and markets. The report will be particularly useful to
companies supplying DNA vaccine components and systems, including synthetic genes, DNA delivery technologies and adjuvants. In addition, the study will benefit a wide range of life-science companies that supply enabling technologies for vaccine discovery and development, such as micro fluidics, nanotechnology, and genomics and proteomics tools.
REASONS FOR DOING THE STUDY
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular biology, DNA synthesis and
immunobiology enable rational design approaches. These technologies allow highly targeted vaccines aimed at specific epitopes. The result is new vaccines for a wider range of diseases than was previously feasible, including a new class of therapeutic vaccines. These new technologies allow pharmaceutical firms to discover and develop high-value vaccines for novel applications, creating a substantial new market opportunity.
DNA vaccines have many potential advantages, including specific targeting, use of multiple genes to enhance immunity, and reduced risk compared with conventional vaccines. Translating the advantages of DNA vaccines into the clinic has historically been difficult; however, new advances in the fields of vaccine design and DNA delivery
are addressing the previous issues. Achievements in these fields promise to overcome the translational hurdles and create strategic opportunity. This report analyzes these
trends and their effects on the future markets for DNA vaccines. The technological and structural changes occurring in the vaccine industry are strong driving forces for revitalizing this particular market and providing new growth opportunities. It is important that biotechnology and pharmaceutical firms understand the technology and market dynamics within this industry in order to best develop strategic plans and actions. Based on these market and technology dynamics, it is especially timely to examine the
future DNA vaccines markets.
We have compiled a study of DNA vaccine technologies that will be commercially important in the major market segments, including cancer, infectious diseases, animal
health, allergies and biodefense. We present DNA vaccine delivery and synthesis technologies, growth driving forces, product formats, market applications, clinical trials, industry structure and alliances, and global sales forecasts for the period from 2014 through 2019. We estimate the future use of DNA vaccines in the important disease markets, and by technology. This report will serve as a useful industry guide for biotechnology, DNA plasmid, gene therapy, DNA delivery, pharmaceutical, vaccine, animal health and biodefense companies, as well as for suppliers of genetic tools, synthetic genes and vaccine adjuvants. It will also be of interest to professionals within the regulatory agencies to understand the scope and pace of DNA vaccine technologies as they move from clinical trials into the market.
SCOPE OF REPORT
The study scope includes DNA vaccine products that are commercial or likely to be commercialized within the next five years. Both human and animal health markets are
studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2014
through 2019 is estimated. The role that DNA vaccines play in the overall vaccines industry is examined, as well as how the vaccine industry structure and dynamics are changing. We examine DNA synthesis, biotechnology and pharmaceuticals firms, strategic industry alliances, and the role of gene delivery and synthesis technologies. The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies and biodefense, are analyzed, and the main companies in these fields are
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
The in situ hybridization market is projected to reach USD 739.9 million by 2021 from USD 557.1 million in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021). Increasing diagnosis and growing ...
The global non-invasive prenatal testing (NIPT) market is projected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021. The major factors driving the ...
The Clustered regularly interspaced short palindromic repeats CRISPR and CRISPR-associated (Cas) genes market is anticipated to reach USD 4.09 billion by 2025, according to a new report by Grand View Research, ...